pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$FOLDAMICUS THERAPEUTICS, INC.

$FOLD14.490.00%
Princeton, NJ, USupdated 3mo ago

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
4
marketed
3
phase 3
1
catalysts ytd
3
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Phase 3: 1Marketed: 3
1Phase 33Marketed
Marketed
cipaglucosidase alfa
Pompe Disease
Marketed
cipaglucosidase alfa + miglustat
Pompe Disease
Marketed
migalastat hydrochloride
Fabry Disease
Phase 3
propagermanium
Focal Segmental Glomerulosclerosis (FSGS)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • —Expanded Access for ATB200/AT2221 for the Treatment of IOPDavailable
  • —A Study of Patients With Fabry Disease (US Specific)recruitingn=450
  • phase3A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variantsrecruitingn=8
  • phase3A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Diseaseactive not recruitingn=14
  • —A Global Prospective Observational Registry of Patients With Pompe Diseaserecruitingn=500
  • phase3A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)completedn=119
  • phase3Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Diseasecompletedn=16
  • —A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.completedn=82
🐶 Hiring Signal
No open roles indexed yet — view AMICUS THERAPEUTICS, INC. jobs →

News

  • AI bio startup Boltz raises $110M Series A
    LONDON — Less than a year after launching from stealth with $28 million, the AI bio startup Boltz has raised a $110 million Series A round, its leaders exclusively told Endpoints News. The ...
    endpoints · 4h ago
  • AstraZeneca, Calidi, Tempest make significant workforce cuts
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 1d ago
  • Ira Mellman wants Parker Institute to restore cancer immunotherapy
    While the whole world was applauding Revolution Medicines' new cancer drug, all Ira Mellman felt was disappointment and frustration. The pill, daraxonrasib, kept patients with advanced pancreatic c…
    endpoints · 6d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 8d ago
  • Sarepta’s new CEO confident in clinical execution as DMD competitors close in
    Sarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.
    biospace · 12d ago
  • Sun Pharma stops eye-care drug production at Indian plant amid quality issues
    The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.
    biospace · 15d ago
  • Opinion: What a mother’s 1834 letter about measles tells us about MAHA
    An 1834 letter about a measles outbreak sheds light on today’s anti-vaccine movement, writes a medical historian.
    stat · 19d ago
  • Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
    Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
    biospace · 22d ago
  • Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
    A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reacti…
    biopharma_dive · 26d ago
  • Opinion: Replication is necessary even if scientists do everything right
    “Committing a Type 1 error does not reflect poorly on the quality of the science done,” writes Mark Louie F. Ramos
    stat · 28d ago
view all news mentions →
identifiers
ticker
$FOLD
SEC CIK
0001178879
country
US
source
sec_tickers
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 46m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?